Vanda Pharmaceuticals has been granted a patent for methods of treating multiple sclerosis using ponesimod. The patent also covers pharmaceutical products containing ponesimod, instructions for use, and methods for reducing clinical management events during treatment. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of multiple sclerosis using ponesimod
A recently granted patent (Publication Number: US11951097B2) discloses a method for reducing clinical management events before or during the treatment of multiple sclerosis using ponesimod. The method involves administering ponesimod in specific doses and schedules as outlined in the drug product label for an approved drug product. The treatment includes an up-titration step at initiation or re-initiation, with doses ranging from 2 mg to 20 mg orally once daily. The method is particularly targeted towards patients with relapsing forms of multiple sclerosis, such as relapsing-remitting disease, clinically isolated syndrome, or active secondary progressive disease.
Furthermore, the patent also covers a method for concomitant treatment with a beta-blocker and ponesimod in patients with resting heart rates above or below 55 beats per minute. The treatment regimen involves administering ponesimod without interruption to the beta-blocker treatment, with specific dosages and titration schedules outlined. The patent also addresses scenarios where doses of ponesimod are missed, providing guidelines for reinitiating treatment with maintenance doses or titration regimens based on the number of consecutive missed doses. Overall, the patent aims to optimize the management of multiple sclerosis by reducing clinical events and providing structured treatment protocols for patients in need of such therapies.
To know more about GlobalData’s detailed insights on Vanda Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
